News & Events
Keep up to date with Isogenica’s latest news on collaborations, Press Releases, Events and VHH antibody resources.
Isogenica’s
Latest News
PRESS RELEASES

Wellmarker Bio signs MoU with Isogenica for the development of multiple therapeutic assets
Wellmarker Bio and Isogenica today announced the signing of a Memorandum of Understanding (MoU). The MoU will serve as a foundation for increased cooperation between the two companies.
Isogenica-Phenotypeca Further Collaboration through Medilink Award
Isogenica-Phenotypeca collaboration spear-headed by SMART Grant award Isogenica are furthering their collaboration with Phenotypeca, whose platform will deploy yeast-display for multivalent...
Isogenica-Phenotypeca SMART Grant Collaboration
Isogenica-Phenotypeca collaboration spear-headed by SMART Grant award Isogenica are collaborating with Phenotypeca, a biofoundry business who create and own yeast synthetic biology solutions...
Announcements
Catch up on Isogenica’s latest activities.
Accelerating antibody discovery with machine learning
A collaboration with the University of Nottingham and Aston University Advances in computing and data science, such as machine learning (ML) and artificial intelligence (AI), are transforming all...
Creating the next generation of immunotherapies with the University of Leicester
Isogenica visiting the team at the University of LeicesterImmunotherapy has transformed the cancer treatment landscape in recent years, harnessing the power of the immune system to target cancer...
CHI Sixth Annual Immuno-Oncology Summit Europe
Join Isogenica in London at the Annunal Immuno-Oncology SummitThe Isogenica team will be attending in person at CHI's annual Immuno-Oncology conference, taking place on 23rd-25th May....
Webinars
Webinars are a great source for the latest activities at Isogenica. Hear all about the newest applications of VHH.
Nature Webinar
Register for Isogenica's upcoming webinar Join Isogenica for the upcoming webinar with Nature on 'VHH as building blocks for immune and tumour cell-targeting', presented by Isogenica's CSO Bill...

Resources
Due to their unique characteristics, VHH are promising candidates for a range of application areas including intracellular targeting and even across the Blood Brain Barrier (BBB). Discover all the benefits in using VHH in different applications.
Neurodegenerative Diseases
The advantages of VHH in Neurodegenerative Diseases.
VHH antibodies as biotherapeutics
Camelid heavy-chain only antibodies were discovered in the early 1990’s. Often referred to as VHH antibodies, they are a well characterized alternative to therapeutic IgG’s. Camelid heavy-chain only...
Upcoming
Events
Isogenica are always looking to learn and connect at upcoming events and conferences.
